A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis12/01/2015 - 11/30/2021 (Co-Investigator)
PI:
Robert W. Simms, MDCorbus Pharmaceuticals Holdings, Inc.
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy volunteers and Subjects with Systemic Lupus Erythematosus04/09/2015 - 04/08/2020 (Co-Investigator)
PI:
Christina Lam, MDBiogen Idec
Scleroderma Clinical Repository (SCaR)10/01/2014 - 09/30/2019 (PI)
Regeneron Pharmaceuticals, Inc.
ASSET: A Phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis - a double-blind, placebo-controlled, randomized controlled trial [IMI101-344]03/31/2015 - 06/30/2019 (Subcontract PI)
Regents of the University of Michigan Bristol-Myers Squibb
Randomized, double-blind, placebo-controlled trial of IL1-Trap, Rilonacept, in Systemic Sclerosis-A Phase I/II Biomarker Trial12/01/2011 - 02/05/2019 (PI)
Regeneron Pharmaceuticals, Inc.
Scleroderma Workshop02/01/2010 - 01/31/2018 (PI)
MedImmune, Inc.
Nox4 Inhibitor in Systemic Sclerosis11/14/2014 - 11/13/2017 (PI)
Mistral Therapeutics, Inc.
NIAMS: CORT09/01/2011 - 08/31/2017 (PI of Sub-Project / SP)
PI:
Robert W. Simms, MDNIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5P50AR060780-05
Rheumatic Diseases Research Core Centers09/01/2011 - 08/31/2017 (PI of Sub-Project / SP)
PI:
Robert W. Simms, MDNIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5P30AR061271-05
A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis-A Phase I/II Biomarker and Safety Trial04/02/2015 - 04/01/2017 (PI)
PRISM Pharma Co Ltd
Showing 10 of 42 results.
Show All Results
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 weeks total) of Epratuzamab in Systematic Lupus06/01/2012 - 12/31/2016 (PI)
UCB Biosciences Inc.
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with System04/25/2012 - 12/31/2016 (PI)
Human Genome Sciences Inc
Evaluation of Topical Imatinib Mesylate in Preclinical Models of Scleroderma09/30/2013 - 09/29/2016 (PI)
PreCision Dermatology, Inc.
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticosteroids08/01/2013 - 07/31/2016 (Co-Investigator)
PI:
Ramon GB Bonegio, MDBristol-Myers Squibb
Inhibitors of Aortic Carboxypeptides-like Proten to Treat Fibroproliferative Diseases01/01/2015 - 07/02/2016 (Co-Investigator)
PI:
Matthew D. Layne, PhDPfizer, Inc.
A Multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of BIIB023 in subjects with Lupus Nephritis04/01/2013 - 05/25/2016 (Co-Investigator)
PI:
Ramon GB Bonegio, MDBiogen Idec
International Workshop on Scleroderma Research06/01/2015 - 04/30/2016 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases2R13AR053784-06
Oncostatin M in Systemic Sclerosis09/19/2014 - 09/30/2015 (PI)
Biogen Idec
Aberrant Recapitulation of Developmental Program: Novel Target in Scleroderma09/30/2012 - 09/29/2015 (PI)
Department of Defense/Army Medical Research Acquisition Activity
Innate immunity in dermal fibrosis and systemic sclerosis07/15/2015 - 08/31/2015 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5R01AR051089-10
A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systematic Systemic Sclerosis10/01/2011 - 03/31/2015 (PI)
F. Hoffmann-La Roche, Ltd.
Shire Phase 1: Testing Anti-CCL2 and Anti-LOXL2 Efficacy in Murine Models of Systemic Sclerosis01/09/2012 - 01/01/2015 (PI)
Shire, Inc.
Double-blind, Randomized, Placebo-controlled, 8-week study investigating the safety, pharmacokinetics and pharmacodynamics of SAR 100842 given orally to patients with diffuse cutaneous systemic scerlo06/12/2012 - 12/31/2014 (PI)
Sanofi-Aventis, U.S., LLC
Biomarkers of Pulmonary Hypertension in Systemic Sclerosis07/01/2006 - 12/31/2014 (PI)
Actelion Pharmaceuticals, Ltd.
International Workshop on Scleroderma Research05/01/2012 - 04/30/2014 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5R13AR053784-05
Shire Phase 1: Testing Anti-CCL2 and Anti-LOXL2 Efficacy in Murine Models of Systemic Sclerosis01/09/2012 - 01/08/2014 (PI)
Shire, Inc.
Pre-Clinical studies of anti-integrin antibodies in systemic sclerosis07/01/2011 - 06/30/2013 (PI)
Stromedix Inc
A Phase II/III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients with Systematic Scleriosis05/01/2012 - 04/30/2013 (PI)
Roche Products Limited
A Phase Ib, Multicenter,Open-Label, Does-Escalating,Repeat-Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept when Administered to Subjects with Lupus N11/01/2011 - 01/31/2013 (PI)
EMD Serono, Inc (Merck)
A Phase Ib, Multicenter,Open-Label, Does-Escalating,Repeat-Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept when Administered to Subjects with Lupus N11/01/2011 - 01/31/2013 (PI)
EMD Serono, Inc (Merck)
Effect of SAR100842 on LPA signature in dermal fibrosis from patients with scleroderma03/01/2012 - 08/31/2012 (PI)
Sanofi-Aventis, U.S., LLC
The Role of Anti-Centromere Antibodies in the Stimulation of Toll-Like Receptor 9 in Systemic Sclerosis07/01/2007 - 06/30/2010 (Co-PI)
Arthritis Foundation
10th International Workshop on Scleroderma Research08/01/2006 - 06/30/2010 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5 R13 AR53784 03
Testing 10015 in cGVHD12/05/2008 - 12/31/2009 (PI)
Celgene Corporation
The Role of Anti-Centromere Antibodies in Stimulation of Toll-like receptor 9 in Systemic Sclerosis01/31/2007 - 12/31/2009 (Co-PI)
Scleroderma Federation
Scleroderma Pulmonary Interstitial Fibrosis11/15/2008 - 11/14/2009 (PI)
Bristol-Myers Squibb
A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study09/01/2008 - 09/01/2009 (PI)
Bristol-Myers Squibb
Rituximab in Scleroderma04/30/2004 - 04/29/2007 (PI)
Genentech, Inc.
Imiquimod in Dermal Fibrosis of Scleroderma09/08/2004 - 09/07/2006 (PI)
3M Pharmaceuticals
International Workshop for Scleroderma Research07/26/2004 - 07/25/2006 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5 R13 AR52187 02
Fibrillin-Binding Matrix and BMPs in TSK Mice and Scleroderma01/04/2004 - 12/31/2005 (PI)
Scleroderma Foundation
mRNA Splicing Regulation by the SWAP Autoantigen07/01/1997 - 06/30/2000 (PI)
Arthritis Foundation